Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 4/20 | 0.49 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14271500 | 0.81 | EGFR (0.46) | EGFRERBB2SMN1; SMN2KMT2APOLB | |
| SCHEMBL17582602 | 0.77 | SMN1; SMN2 (0.56) | EGFRERBB2SMN1; SMN2KMT2APOLB | |
| SCHEMBL4956996 | 0.75 | EGFR (0.43) | EGFRERBB2MAPTL3MBTL1TP53 | |
| SCHEMBL7080177 | 0.75 | EGFR (0.41) | EGFRERBB2SMN1; SMN2KMT2APOLB | |
| SCHEMBL13495282 | 0.74 | SMN1; SMN2 (0.61) | SMN1; SMN2KMT2APOLBMAPK1TDP1 | |
| SCHEMBL15920987 | 0.74 | SMN1; SMN2 (0.61) | SMN1; SMN2KMT2APOLBF2RL3MAPK1 | |
| SCHEMBL1242317 | 0.74 | SMN1; SMN2 (0.49) | EGFRERBB2SMN1; SMN2KMT2APOLB | |
| SCHEMBL25604982 | 0.73 | MAPK1 (0.52) | EGFRERBB2SMN1; SMN2KMT2APOLB | |
| SCHEMBL21332805 | 0.73 | SMN1; SMN2 (0.77) | SMN1; SMN2KMT2APOLBMAPK1TDP1 | |
| SCHEMBL30645297 | 0.73 | TSHR (0.49) | SMN1; SMN2POLBF2RL3MAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7332149-B1 | Vitronectin receptor antagonist pharmaceuticals | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-02-19 | — | — | US | disclosed |
| US-7321045-B2 | Vitronectin receptor antagonist pharmaceuticals | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-01-22 | — | — | US | disclosed |
| EP-1140203-B1 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2007-05-23 | — | — | EP | disclosed |
| US-20050154185-A1 | Vitronectin receptor antagonist pharmaceuticals | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2005-07-14 | — | — | US | disclosed |
| US-6838074-B2 | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-01-04 | — | — | US | disclosed |
| US-20040208823-A1 | SIMULTANEOUS IMAGING OF CARDIAC PERFUSION AND A VITRONECTIN RECEPTOR TARGETED IMAGING AGENT | LANTHEUS MEDICAL IMAGING, INC. | 2004-10-21 | — | — | US | disclosed |
| US-6794518-B1 | Vitronectin receptor antagonist pharmaceuticals | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-09-21 | — | — | US | disclosed |
| EP-1296678-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS FOR USE IN COMBINATION THERAPY | Bristol-Myers Squibb Pharma Company (US) | 2003-04-02 | — | — | EP | disclosed |
| WO-2001098294-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS FOR USE IN COMBINATION THERAPY | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-12-27 | — | — | WO | disclosed |
| EP-1140203-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | Du Pont Pharmaceuticals Company (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000035488-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040208823-A1 | SIMULTANEOUS IMAGING OF CARDIAC PERFUSION AND A VITRONECTIN RECEPTOR TARGETED IMAGING AGENT | TNNI3, ASGR1, TNNT2 | EGFR 576/4885ERBB2 621/4885SMN1; SMN2 3113/4885 |
| US-20050154185-A1 | Vitronectin receptor antagonist pharmaceuticals | ADGRF1, RXFP1, VCAM1 | EGFR 265/4885ERBB2 391/4885SMN1; SMN2 3978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.